MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319719 | Name: Pocapavir
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pocapavir, also known as SCH-48973 and V-073, is a potent, selective, antienterovirus agent. SCH-48973 had antiviral activity (50% inhibitory concentrations [IC50s]) of 0.02 to 0.11 microg/ml, with no detectable cytotoxicity at 50 microg/ml. SCH-48973 inhibited 80% of 154 recent human enterovirus isolates at an IC50 of 0.9 microg/ml. The affinity constant (Ki) for SCH-48973 binding to poliovirus was 8.85 x 10(-8) M. SCH-48973 demonstrated efficacy in a murine poliovirus model of enterovirus disease. SCH-48973 represents a potential candidate for therapeutic intervention against enterovirus infections.

Chemical Structure

Pocapavir
Pocapavir
CAS#146949-21-5

Theoretical Analysis

MedKoo Cat#: 319719

Name: Pocapavir

CAS#: 146949-21-5

Chemical Formula: C21H17Cl3O3

Exact Mass: 422.0243

Molecular Weight: 423.71

Elemental Analysis: C, 59.53; H, 4.04; Cl, 25.10; O, 11.33

Price and Availability

Size Price Availability Quantity
10mg USD 125.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 1,950.00 Ready to ship
1g USD 2,650.00 Ready to ship
2g USD 3,950.00 Ready to ship
5g USD 6,950.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SCH-48973; SCH48973; SCH 48973; V074; V 073; V-073; Pocapavir.
IUPAC/Chemical Name
1,3-dichloro-2-((4-((2-chloro-4-methoxyphenoxy)methyl)benzyl)oxy)benzene
InChi Key
XXMDDBVNWRWNCW-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H17Cl3O3/c1-25-16-9-10-20(19(24)11-16)26-12-14-5-7-15(8-6-14)13-27-21-17(22)3-2-4-18(21)23/h2-11H,12-13H2,1H3
SMILES Code
ClC1=C(OCC2=CC=C(COC3=CC=C(OC)C=C3Cl)C=C2)C(Cl)=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Pocapavir (SCH-48973, V-073) is an inhibitor of investigational enterovirus (EV) capsid.
In vitro activity:
To assess the spectrum of antipoliovirus activity of V-073, a panel of 45 polioviruses was assembled and evaluated in a cell culture cytopathic effect assay. The panel consisted of viruses from all three poliovirus serotypes and included wild reference strains. The assay for drug susceptibility measured protection by the drug of an LLC-MK2 cell monolayer from the virus replication-induced cytopathic effect. The 50% effective concentration (EC50) values for the 45 individual viruses, as determined from seven-point concentration curves using a four-parameter curve-fitting program (SoftMax Pro; Molecular Devices), are provided in Table 1. V-073 was active against all viruses in this panel, with EC50s ranging from 0.003 μM to 0.126 μM. The distribution of drug susceptibilities among these 45 polioviruses is depicted in Fig. 2. Ninety percent of all polioviruses tested were inhibited by V-073 at EC50s of ≤0.076 μM (MIC90 = 76 nM; 32 ng/ml). In Table Table2,2, the mean EC50s for the various categories of polioviruses are provided. There appears to be no bias in the activity of V-073 among these virus groupings. Reference: Antimicrob Agents Chemother. 2009 Oct;53(10):4501-3. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19635956/
In vivo activity:
For mice infected with poliovirus type 2 and treated (beginning either 6 or 24 h after infection) with SCH 48973 at 20 mg/kg/day, there was a significant reduction (1 to 2 logs) in the titer of virus recovered from the brains 2 days after infection (Table 2). The difference between the two regimens (6 and 24 h) was not significant. When brains from noninfected, SCH 48973-treated mice were removed, homogenized, diluted, and inoculated in vitro with known quantities of virus, no reduction of viral plaques compared to the input inoculum was observed (data not shown). These results indicate that the reduction in viral load in brains is due to a direct effect of SCH 48973 in vivo and not due to compound carryover into the tissue culture system. Reference: Antimicrob Agents Chemother. 1997 Jun;41(6):1220-5. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/9174174/
Solvent mg/mL mM comments
Solubility
DMSO 100.0 236.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 423.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother. 2009 Oct;53(10):4501-3. doi: 10.1128/AAC.00671-09. Epub 2009 Jul 27. PMID: 19635956; PMCID: PMC2764203. 2. Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother. 1997 Jun;41(6):1220-5. doi: 10.1128/AAC.41.6.1220. PMID: 9174174; PMCID: PMC163890.
In vivo protocol:
1. Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. SCH 48973: a potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother. 1997 Jun;41(6):1220-5. doi: 10.1128/AAC.41.6.1220. PMID: 9174174; PMCID: PMC163890.
1: Ranchod H, Howard W, Roux A, van Zyl W, Ekermans P, van den Berg S, Seakamela L, Makua K, Yousif M, Sibiya R, Du Plessis H, Phalane E, McCarthy K, Moonsamy S, Reynders D, Hincks J, Suchard MS, du Plessis NM. Stem Cell Transplant in Immune- deficiency-associated Vaccine-derived Poliovirus. Open Forum Infect Dis. 2024 Jan 17;11(2):ofad678. doi: 10.1093/ofid/ofad678. PMID: 38328499; PMCID: PMC10849832. 2: Chandran D, Chakraborty S, Ahmed SK, Chopra H, Islam MR, Dhama K. France Reports Rise in Severe Neonatal Infections Caused by a New Enterovirus (Echovirus-11) Variant. Clin Pathol. 2023 Nov 17;16:2632010X231213793. doi: 10.1177/2632010X231213793. PMID: 38022906; PMCID: PMC10657519. 3: Tomatis Souverbielle C, Erdem G, Sánchez PJ. Update on nonpolio enterovirus and parechovirus infections in neonates and young infants. Curr Opin Pediatr. 2023 Jun 1;35(3):380-389. doi: 10.1097/MOP.0000000000001236. Epub 2023 Mar 3. PMID: 36876331. 4: Glassman KF, Brugge JS, Purchio AF, Kakach LT, Fuerst TR, Woods RM, Stover CK, Chunduru SK, Hincks JR, McKinlay MA, Nash CH, Pevear DC, Monath TP, Rice CM, Peters P. Biographical Feature: Marc S. Collett (23 May 1951-11 June 2022): the Battle against Viral Disease Has Lost a Valiant Warrior, and the World Has Lost a Splendid Human Being. J Virol. 2023 Jan 31;97(1):e0164322. doi: 10.1128/jvi.01643-22. Epub 2022 Dec 5. PMID: 36468860; PMCID: PMC9888289. 5: Grammatikos A, Bright P, Pearson J, Likeman M, Gompels M. Chronic Enteroviral Meningoencephalitis in a Patient with Good's Syndrome Treated with Pocapavir. J Clin Immunol. 2022 Nov;42(8):1611-1613. doi: 10.1007/s10875-022-01321-6. Epub 2022 Jul 23. PMID: 35870029; PMCID: PMC9700624. 6: Epstein S, Thakkar R, Fong KT, Ng J, Bearden DR, Mishra N, Thakur KT, Riley CS. Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis. J Neurovirol. 2022 Apr;28(2):329-334. doi: 10.1007/s13365-021-01038-z. Epub 2022 Jan 3. PMID: 34981437. 7: Kankam MK, Burns JM, Collett MS, Corrado ML, Hincks JR. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0102921. doi: 10.1128/AAC.01029-21. Epub 2021 Aug 9. PMID: 34370575; PMCID: PMC8448163. 8: Álamo-Junquera D, Politi J, Simón P, Dieli-Crimi R, Borrell RP, Colobran R, Martínez-Gallo M, Campins M, Antón A, Esperalba J, Andrés C, Codina MG, Polverino E, Narciso MR, Molinero E, Rius C. Coordinated Response to Imported Vaccine-Derived Poliovirus Infection, Barcelona, Spain, 2019-2020. Emerg Infect Dis. 2021 May;27(5):1513-1516. doi: 10.3201/eid2705.204675. PMID: 33900188; PMCID: PMC8084499. 9: Zhang M, Wang H, Tang J, He Y, Xiong T, Li W, Qu Y, Mu D. Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatr. 2021 Mar 15;21(1):127. doi: 10.1186/s12887-021-02599-y. PMID: 33722228; PMCID: PMC7958388. 10: Copelyn J, Hincks JR, Wilmshurst JM, Petersen W, Howard W, Jallow S, Moonsamy S, Seakamela L, Suchard M, Collett MS, Eley B. Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection With Pocapavir. Pediatr Infect Dis J. 2020 May;39(5):435-437. doi: 10.1097/INF.0000000000002584. PMID: 32150007. 11: Brickley EB, Connor RI, Wieland-Alter WF, Collett MS, Hartford M, Van Der Avoort H, Boesch AW, Weiner JA, Ackerman ME, McKinlay MA, Arita M, Bandyopadhyay AS, Modlin JF, Wright PF. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health. 2019 Aug 28;4(4):e001613. doi: 10.1136/bmjgh-2019-001613. PMID: 31543993; PMCID: PMC6730592. 12: Amdani SM, Kim HS, Orvedahl A, John AO, Said A, Simpson K. Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir. BMJ Case Rep. 2018 May 18;2018:bcr2017224133. doi: 10.1136/bcr-2017-224133. PMID: 29776940; PMCID: PMC5965763. 13: Harik N, DeBiasi RL. Neonatal nonpolio enterovirus and parechovirus infections. Semin Perinatol. 2018 Apr;42(3):191-197. doi: 10.1053/j.semperi.2018.02.007. Epub 2018 Mar 9. PMID: 29526382. 14: Wittekind SG, Allen CC, Jefferies JL, Rattan MS, Madueme PC, Taylor BN, Moore RA. Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment With Pocapavir. J Investig Med High Impact Case Rep. 2017 Sep 14;5(3):2324709617729393. doi: 10.1177/2324709617729393. PMID: 28944227; PMCID: PMC5602221. 15: Sutter RW, Modlin JF, Zaffran M. Completing Polio Eradication: The Case for Antiviral Drugs. J Infect Dis. 2017 Feb 1;215(3):333-334. doi: 10.1093/infdis/jiw547. PMID: 27932609. 16: Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017 Feb 1;215(3):335-343. doi: 10.1093/infdis/jiw542. PMID: 27932608; PMCID: PMC5393058. 17: Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy. J Allergy Clin Immunol Pract. 2016 Nov-Dec;4(6):1059-1065. doi: 10.1016/j.jaip.2015.12.015. Epub 2016 Feb 13. PMID: 26883540. 18: McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. PMID: 25316866. 19: Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ. First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. Pediatr Infect Dis J. 2015 Jan;34(1):52-4. doi: 10.1097/INF.0000000000000497. PMID: 25229269. 20: Liu HM, Roberts JA, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS, Oberste MS. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother. 2012 Nov;56(11):5568-74. doi: 10.1128/AAC.00539-12. Epub 2012 Aug 13. PMID: 22890765; PMCID: PMC3486616.